首页> 外文期刊>Human vaccines >Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
【24h】

Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.

机译:对基于乳杆菌奈瑟菌外膜囊泡的脑膜炎球菌疾病疫苗的关键抗原成分和临床前免疫反应的表征。

获取原文
获取原文并翻译 | 示例
       

摘要

Serogroup B strains are now responsible for over 80% of meningococcal disease in the UK and no suitable vaccine is available that confers universal protection against all serogroup B strains. Neisseria lactamica shares many antigens with the meningococcus, except capsule and the surface protein PorA. Many of these antigens are thought to be responsible for providing cross-protective immunity to meningococcal disease. We have developed an N. lactamica vaccine using methods developed for meningococcal outer membrane vesicle (OMV) vaccines. The major antigenic components were identified by excision of 11 major protein bands from an SDS-PAGE gel, followed by mass spectrometric identification. These bands contained at least 22 proteins identified from an unassembled N. lactamica genome, 15 of which having orthologues in published pathogenic Neisseria genomes. Western blotting revealed that most of these bands were immunogenic, and antibodies to these proteins generally cross-reacted with N. meningitidis proteins. Sera from mice and rabbits immunized with either N. lactamica or N. meningitidis OMVs produced comparable cross-reactive ELISA titres against OMVs prepared from a panel of diverse meningococcal strains. Mice immunized with either N. meningitidis or N. lactamica OMVs showed no detectable serum bactericidal activity against the panel of target strains except N. meningitidis OMV sera against the homologous strain. Similarly, rabbit antisera to N. lactamica OMVs elicited little or no bactericidal antibodies against the panel of serogroup B meningococcal strains. However, such antisera did mediate opsonophagocytosis, suggestingthat this may did mediate opsonophagocytosis, suggesting that this may be a mechanism by which this vaccine protects in a mouse model of meningococcal bacteraemia.
机译:在英国,血清群B毒株现在引起了80%的脑膜炎球菌疾病,目前尚无合适的疫苗可以针对所有血清群B毒株提供普遍保护。乳酸奈瑟菌与脑膜炎球菌共享许多抗原,除了荚膜和表面蛋白PorA。这些抗原中的许多被认为负责提供针对脑膜炎球菌疾病的交叉保护性免疫。我们已经使用针对脑膜炎球菌外膜囊泡(OMV)疫苗开发的方法开发了一种乳酸奈瑟氏球菌疫苗。通过从SDS-PAGE凝胶中切除11条主要蛋白条带,鉴定主要抗原成分,然后进行质谱鉴定。这些条带包含至少22种蛋白质,这些蛋白质是从未组装的乳酸奈瑟菌基因组中鉴定的,其中15种在已发表的致病性奈瑟氏菌基因组中具有直向同源物。蛋白质印迹显示,大多数这些条带是免疫原性的,针对这些蛋白质的抗体通常会与脑膜炎奈瑟氏球菌蛋白质发生交叉反应。来自用乳杆菌或脑膜炎奈瑟氏菌OMV免疫的小鼠和兔子的血清产生的抗交叉ELISA效价与一组不同的脑膜炎球菌菌株制备的OMV相当。除脑膜炎奈瑟氏菌OMV血清针对同源菌株外,用脑膜炎奈瑟氏球菌或内酰胺奈瑟氏菌OMV免疫的小鼠均未检测到针对目标菌株组的可检测血清杀菌活性。类似地,针对乳杆菌N.lactamica OMV的兔抗血清很少或没有引起针对血清群B脑膜炎球菌菌株的杀菌抗体。但是,这种抗血清确实介导了调理吞噬作用,表明这可能确实调理了调理吞噬作用,表明这可能是该疫苗在脑膜炎球菌菌血症小鼠模型中起到保护作用的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号